37 results about "Medulloblastoma" patented technology

The present invention concerns compounds that selectively inhibit the activity of the Hedgehog (Hh) pathway, their preparation and uses thereof. The compounds of the present invention are useful in treating Hh-dependent tumors, such as medulloblastoma (MB).

The invention, which belongs to the field of traditional Chinese medicines, particularly discloses application of an alcohol extract of eucalyptus globulus labill. fruit and components in preparationof a medicine for preventing and/or treating anti-medulloblastoma. Effective components of fruits of eucalyptus globulus labill. are extracted; and activity screening is performed by utilizing medulloblastoma cells. Experimental results show that the eucalyptus globulus labill. fruit alcohol extract and the components thereof can effectively inhibit the proliferation activity of medulloblastoma and have the broad application prospects in the aspect of preparation and development of drugs for treating tumor diseases.

The invention provides a medulloblastoma animal model and establishment and application thereof. The expression or activity of the Patched protein in the animal model cell is reduced, and the expression or activity of the Trim32 protein is reduced. The invention also provides a construction method of the non-human mammal model and a preparation method of the non-human mammal model of medulloblastoma carrying the cerebellar precursor cell marker and the early differentiated cell marker at the same time. The non-human mammal model is a more effective myeloblastoma (MB) model, the morbidity of MBis greatly improved compared with an existing classic model, and the non-human mammal model can be used as an excellent animal model for drug screening and experimental research.

The invention belongs to the technical field of preparation of tumor diagnosis/prognosis reagents, and particularly relates to a medulloblastoma/cell marker and application thereof. The invention relates to the research and application of the protein in the SMO-activated mutant medulloblastoma/cell based on one or more of GPR37 protein, RAB35 protein, RPS10 protein, NUDT3 protein, USP6NL protein, REE protein, CACYBP protein and CKAP5 protein. The specific conjugates of the proteins are prepared into kits or reagents, so that the myeloblastoma/cells can be diagnosed/prognosed more simply, conveniently and accurately, and particularly, the drug-resistant myeloblastoma/cells can be screened more accurately, and then the drugs are applied according to the case.

The invention provides a method of inhibiting casein kinase 1 DETA (CK1 DETA), comprising contacting the CK1 DETA with a compound of formula (I), as defined herein; such as compound SR-3029. We demonstrate that CSNK1D is amplified and/or overexpressed in human breast tumors and that CK1 delta can be medically targeted in human breast cancer subtypes overexpressing this kinase. The invention further provides a method of treating cancer, such as a breast cancer, melanoma, glioblastoma, medulloblastoma, renal, bladder or colon cancer, or a cancer that metastasizes to the brain, lung, or bone provided that both elevated CK1 DETA and BETA-catenin dependence are involved in those metastatic diseases. The cancer can be a breast cancer of the triple negative subclass of breast cancers (TNBC), or can be an HER+ breast cancer.

The invention provides a culture solution for culturing brain tumor cells in vitro. The culture solution comprises a nerve cell basal medium, and also comprises, based on the mass of the nerve cell basal medium, 0.5%-5% of a B27 trophic factor, 0.5%-5% of double antibodies- penicillin/streptomycin, 0.5%-5% of glutamine, 0.5%-5% of sodium pyruvate, 0.5%-1.5% of fetal bovine serum, and 2.5- 3.5 microgram/mL of recombinant Shh proteins. Cells obtained by applying the culture solution can proliferate and produce offspring, the Shh signaling pathway is in an activated expression state, the tumorigenicity is not affected, and the cells can withstand cryopreservation of 80 DEG C and achieve adherent differentiation, and thus a unique cell model is provided for studying the molecular mechanism ofmedulloblastoma development and the molecular mechanism of Shh signaling pathway regulation and an important tool is provided for high-throughput screening of chemotherapy drugs.

The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods useful for detecting long non-coding RNAs (lncRNA) in medulloblastoma. In one embodiment, the present invention provides a method comprising detecting lnc RNA HLX2-7 in a biological sample obtained from a patient having or suspected of having medulloblastoma. In certain embodiments, detecting step is performed using RNA fluorescence in situ hybridization (FISH) assay. In specific embodiments, the biological sample is a tissue sample. In particular embodiments, the tissue sample is a formalin-fixed paraffin-embedded (FFPE) sample. In a specific embodiment, the FISH assay comprises oligonucleotide probes that hybridize to lncHLX2-7 (SEQ ID NO:200) and branched DNA signal amplification.

Disclosed herein are analogues of itraconazole that are both angiogenesis and hedgehog signaling pathway inhibitors, formulations thereof, including lipsome formulations thereof. The compounds are expected to be useful in the treatment of cell proliferation disorders such as cancer, particularly cancers that are dependent upon the hedgehog signaling pathway such as basal cell carcinoma and medulloblastoma.

The invention belongs to the technical field of biology, and particularly relates to application of Kir2.1 as a target spot to preparation of a reagent or a medicine for treating, preventing or diagnosing medulloblastoma. The invention has important clinical application value for diagnosis, treatment and prevention of WNT/SHH medulloblastoma.

The invention relates to a compound with an inhibition effect on activation of hedgehog pathways. The structural formula of the compound is shown in formula (1), wherein R is H or CH3. The invention also provides a method for preparing the compound. The invention also provides an application of the compound or pharmaceutically acceptable salt, a solvate or a medicine compound of the compound to preparation of drugs for treating diseases related to activation of hedgehog pathways. The compound can be used for preparing the drugs for treating diseases related to activation of hedgehog pathways.The compound can particularly well inhibit growth of medulloblastoma and can be used for preparing drugs for treating medulloblastoma related diseases.

Brain tumors remain the leading cause of cancer-related deaths in children and often are associated with long-term sequelae among survivors of current therapies. Telomerase and telomeres play important roles in cancer, representing attractive therapeutic targets to treat children with poor-prognosis brain tumors such as diffuse intrinsic pontine glioma (DIPG), high-grade glioma (HGG) and high-risk medulloblastoma (MB). It has shown that DIPG, HGG and MB frequently express telomerase activity. It is now shown that the telomerase-dependent incorporation of 6-thio-2′deoxyguanosine (6-thio-dG), a telomerase substrate precursor analog, into telomeres leads to telomere dysfunction-induced foci (TIFs) along with extensive genomic DNA damage, cell growth inhibition and cell death of primary stem-like cells derived from patients with DIPG, HGG and MB. Importantly, the effect of 6-thio-dG is persistent even after drug withdrawal. Treatment with 6-thio-dG elicits a sequential activation of ATR and ATM pathways and induces G₂/M arrest. In vivo, treatment of mice bearing MB xenografts with 6-thio-dG delays tumor growth, increases in-tumor TIFs and apoptosis. Furthermore, 6-thio-dG crosses the blood-brain barrier and specifically targets tumor cells in an orthotopic mouse model of DIPG. Together, these findings suggest that 6-thio-dG is a promising approach to treat therapy-resistant telomerase-positive pediatric brain tumors.